Navigation Links
Dendreon Announces Presentation of Data at American Urological,Association Annual Meeting

mized Phase 3 trials (D9901 and D9902A; n=225) conducted in men with asymptomatic, metastatic, androgen independent prostate cancer. Survival analyses were performed on the subgroup of 82 patients in the trials that were documented to have received docetaxel chemotherapy following initial treatment with either PROVENGE or placebo.

According to the analysis, the patients who received initial treatment with PROVENGE followed by docetaxel had a median survival of 34.5 months compared to 25.4 months for those patients in the placebo arm who received treatment with docetaxel chemotherapy, a 9.1 month difference. In addition, an analysis of overall survival demonstrated that patients in the PROVENGE arm who received subsequent therapy with docetaxel had a 47 percent reduction in their risk of death compared to those in the placebo arm who received subsequent therapy with docetaxel (HR = 1.90, p-value = 0.023).

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007, and more than 27,000 men expected to die this year from the disease.

About PROVENGE

PROVENGE (sipuleucel-T) is an investigational product that may represent the first in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. PROVENGE is in late-stage clinical development for the treatment of patients with early-stage and advanced prostate cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the im
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: ... development and commercialization of products for central nervous ... two posters at the Society for Research on ... The first poster entitled Pleiomorphic ... provides insight into the challenges faced by ...
(Date:5/22/2012)... -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it ... and Drug Administration for its abbreviated new drug ... the generic equivalent of Gynazole·1®. Perrigo was the first ... a paragraph IV certification and is entitled to ... KV Pharmaceutical Company on a collaboration to launch ...
(Date:5/22/2012)... AUSTIN, Texas, May 22, 2012  Prodigy Generics, ... has launched injectable irinotecan. Irinotecan is the generic ... Prodigy partnered with eVenus Pharmaceutical Laboratories ... is the first of several ANDAs being developed ... and exceptional value to the U.S. injectable market, ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3Infant Organ Donors Could Help Meet Transplant Needs 3A Study 78200 1Infant Organ Donors Could Help Meet Transplant Needs 3A Study 78200 2Scripps Research chemist devises new method to quantify protein changes 17165 1Scripps Research chemist devises new method to quantify protein changes 17165 2Scripps Research chemist devises new method to quantify protein changes 17165 3Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC 1002 13706 1Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC 1002 13706 2
... Age: Comparison by Interventional Radiologists Shows No Difference ... DIEGO, March 9 A new study shows ... it doesn,t matter if you,re young or old: ... maintaining access to one,s circulatory system to provide ...
... dosed every two weeks met the primary efficacy ... alfa-2a dosed weekly in patients with genotype 1 ... Albuferon had comparable rates of serious and/or severe ... global marketing applications planned in fall 2009 -ROCKVILLE, ...
Other Medicine Technology:For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold 2For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold 3For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10
(Date:5/23/2012)... In one of the most comprehensive analyses to ... prostate cancer, researchers at UPMC found that this now-dominant ... surgery, despite little scientific evidence of long-term improved patient ... and will appear in the July issue of the ... the first studies based on actual direct and indirect ...
(Date:5/23/2012)... connections as we age help keep us sharp in later ... found. , Older people with robust brain ,wiring, that ... can process information quickly and that this makes them ... findings, joining distant parts of the brain together with better ... in a single part of the brain. , However ...
(Date:5/23/2012)... use of physical restraints in nursing homes can ... more training and supportive materials for staff, residents ... Despite legal regulations and evidence that they ... and belts still are frequently used in nursing ... of physical-restraint use in U.S. nursing homes is ...
(Date:5/23/2012)... ROCHESTER, Minn. -- Mayo Clinic researchers will present ... other urological research at the annual meeting of ... Mayo Clinic urologists will also be available to ... , Mayo Clinic studies that will be presented ... negative impact on overall survival from post-prostate surgery ...
(Date:5/22/2012)... Storrs HealthDay Reporter , , TUESDAY, May 22 ... sleep apnea, a common cause of snoring and daytime ... hazard associated with the condition -- the risk of ... the number of new cases of high blood pressure ... positive airway pressure therapy, or CPAP, for either about ...
Breaking Medicine News(10 mins):Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 3Health News:Well-connected brains make you smarter in older age 2Health News:Study Offers Ways to Decrease Use of Restraints at Nursing Homes 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Sleep Apnea 'Mask' Might Also Help the Heart 2Health News:Sleep Apnea 'Mask' Might Also Help the Heart 3Health News:Sleep Apnea 'Mask' Might Also Help the Heart 4
... Allergies Send 50,000 Americans to the Emergency Room Annually , ... new study from the Mayo Clinic published in the December issue ... indicates a higher incidence of anaphylactic reactions than previously reported. ... "The etiology and incidence of anaphylaxis in Rochester, Minnesota," Wyatt W. ...
... December 11, 2008 The American Cancer Society ... Terry Awards for Exemplary Leadership in Tobacco Control. The ... General Luther L. Terry, M.D., who led the landmark ... lung cancer and other illnesses. Dr. Terry,s courageous and ...
... Research Group (MRG) analyst Deanna Vankessel, author of the recently published ... report, is available to offer extensive expertise on the recent FDA ... the knee. , , MRG,s ... , , , ...
... Expected to Begin in December - , , ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: ... trial of neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. ... with advanced breast cancer positive for the ErbB-2 receptor (also known ...
... Female Health Company (NYSE Alternext: FHC) has announced that the ... Advisory Committee has unanimously voted that the company,s second-generation female ... condition. , , The ... the condition that the FC2 Female Condom,s instructions for use ...
... with ribavirin for previously untreated children with chronic hepatitis ... , KENILWORTH, N.J., Dec. 12 Schering-Plough ... the U.S. Food and Drug Administration (FDA) has granted ... USP) combination therapy for use in previously untreated patients ...
Other Medicine News:Health News:Incidence of Anaphylaxis Higher Than Previously Reported 2Health News:Incidence of Anaphylaxis Higher Than Previously Reported 3Health News:American Cancer Society recognizes international tobacco control leaders 2Health News:American Cancer Society recognizes international tobacco control leaders 3Health News:American Cancer Society recognizes international tobacco control leaders 4Health News:American Cancer Society recognizes international tobacco control leaders 5Health News:American Cancer Society recognizes international tobacco control leaders 6Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7
... CryoCath has developed a minimally ... reentrant tachycardia. It delivers a very ... site confirmation, pinpoint site precision, minimal ... thrombus and stenosis., ,Freezor Xtra allows ...
... CryoCath has developed a minimally invasive ... tachycardia. It delivers a very high ... confirmation, pinpoint site precision, minimal tissue ... and stenosis., ,Freezor is a flexible, ...
The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
Ten-Ten duodecapolar diagnostic mapping catheters are available in four curve sizes....
Medicine Products: